Finding effective treatments for multiple sclerosis is our number one priority at the MS Society and this is a big moment.’
Dr Klaus Schmierer of Queen Mary University of London, said: ‘This is great news for everybody affected by MS, and society as a whole.
‘People with primary progressive MS and clinicians alike have been eagerly waiting for an effective treatment to slow the path of relentless deterioration.’
The data showed that patients with primary progressive MS saw the progress of their disability slowed by 24 per cent over just 12 weeks, when compared with patients who took a ‘dummy’ placebo.
Patients with relapsing MS saw a 47 per cent reduction in relapse rate, when compared to an older product called Rebif. The progression of their disability also slowed by 40 per cent.
Read more
No comments:
Post a Comment